Edgewise Therapeutics (EWTX) said Monday that a phase 2 trial of sevasemten to treat patients with Becker muscular dystrophy met its primary endpoint of change from baseline in creatine kinase.
The biopharmaceutical company also said the key secondary endpoint of function demonstrated an improving trend over time in the sevasemten-treated group. It added the drug was well-tolerated, with no new safety concerns in adult or adolescent patients.
Shares of Edgewise Therapeutics were up 22% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。